Experience of the use of combination of dabrafenib and trametinib in patients with metastatic skin melanoma in real clinical practice in Russia
- Authors: Samoylenko I.V1, Demidov L.V1
-
Affiliations:
- FSBI “RORC n.a. N.N. Blokhin" of RMH
- Issue: No 8 (2017)
- Pages: 12-18
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289846
- ID: 289846
Cite item
Open Access
Access granted
Abstract
Over the past 5 years, the treatment of metastatic and irresectable melanoma has undergone significant changes. Large clinical trials have shown high efficacy of new drugs. The experience of using a combination of dabrafenib and trametinib in the framework of the Program of expanded access to these drugs in Russia was analyzed. In the period from March 2015 to June 2015, the program included 14 patients. The median age was 45 years (range - 30-63), 38.5% male; BRAF V600Emutation was detected in the tumor in all patients. 84.6% of patients had ECOG performance status score of 0-1, M1c stage of disease was determined in 76.9% of patients. The elevated lactate dehydrogenase levels were detected in 46.2% of patients. 53.8% of patients received two or more lines of the previous therapy. The frequency of objective responses to treatment was 61.5%, stabilization - 15.4%, progression - 23.1%. The median progression-free survival was 7.29 months (95% CI 3.74-10.84), a 2-year progression-free survival rate - 22%. The median overall survival was 13.27 months (95% CI - 10.3-16.2 months), a two-year overall survival rate - 43%. During the study, there were no serious adverse events associated with medications. Also, there were no new adverse events. It was concluded that the combination of BRAF inhibitor and MEK inhibitor - dabrafenib and trametinib - is a highly effective and well tolerated treatment for metastatic or unresectable melanoma with a BRAF V600 mutation in the first and subsequent lines of therapy. The data of the above mentioned expanded access program are consistent with the results of previous randomized trials.
Keywords
Full Text
About the authors
I. V Samoylenko
FSBI “RORC n.a. N.N. Blokhin" of RMH
Email: i.samoylenko@ronc.ru
L. V Demidov
FSBI “RORC n.a. N.N. Blokhin" of RMH
References
- Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011;364(26):2507-16.
- Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H. Jr, Kaempgen E., Martin-Algarra S., Karaszewska B., Mauch C., Chiarion-Sileni V., Martin A.M., Swann S., Haney P., Mirakhur B., Guckert M.E., Goodman V., Chapman P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012,380(9839):358-65.
- Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., Chiarion-Sileni V, Lebbe C., Mandalà M., Millward M., Arance A., Bondarenko I., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-51.
- Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., Lichinitser M., Dummer R., Grange F., Mortier L., Chiarion-Sileni V., Drucis K., Krajsova I., Hauschild A., Lorigan P., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015;372(1):30-9.
- Larkin J., Hodi F.S., Wolchok J.D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015;373(13):1270-71.
- Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J., Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni V., et al: Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015;372(4): 320-30.
- Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., lannone R., Ebbinghaus S.W., Kang S.P, Daud A. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-17.
- Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., Larkin J., Lorigan P., Neyns B., Blank C.U., Hamid O., Mateus C., Shapira-Frommer R., Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., Ribas A.; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015;372(26):2521-32.
- Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009;45(2): 228-47.
- Atkinson V., Long G.V., Menzies A.M., McArthur G., Carlino M.S., Millward M., Roberts-Thomson R., Brady B., Kefford R., Haydon A., Cebon J. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia Pac. J. Clin. Oncol. 2016;12(Suppl 7):5-12.
- Larkin J., Ascierto P.A., Dreno B., Atkinson V., Liszkay G., Maio M., Mandala M., Demidov L., Stroyakovskiy D., Thomas L., dela Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014;371(20):1867-76.
- Long G.V., Weber J.S., Infante J.R., Kim K.B., Daud A., Gonzalez R., Sosman J.A., Hamid O., Schuchter L., Cebon J., Kefford R.F, Lawrence D., Kudchadkar R., Burris H.A. 3rd, Falchook G.S., Algazi A., Lewis K., Puzanov I., Ibrahim N., Sun P., Cunningham E., Kline A.S., Del Buono H., McDowell D.O., Patel K., Flaherty K.T. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J. Clin. Oncol. 2016;34(8):871-78.
- Johnson D.B., Flaherty K.T., Weber J.S., Infante J.R., Kim K.B., Kefford R.F., Hamid O., Schuchter L., Cebon J., Sharfman W.H., McWilliams R.R., Sznol M., Lawrence D.P., Gibney G.T., Burris H.A. 3rd, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol. 2014;32(33):3697-704.
- Daud A., Pavlick A.C., Ribas A., Gonzalez R., Lewis K.D., Hamid O., Gajewski T., Puzanov I., Hsu J.J., Koralek D.O., et al. Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma. J. Clin. Oncol. 2016;34(suppl):abstr 9510.
Supplementary files
